StockData
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. (PTHS) stock

PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$6.84−0.31 (-4.34%)

Close on Nov 17, 2026Market cap $26.19MP/E –Yield –

Pelthos Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Pelthos Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.31M, down 7.4% year over year. For fiscal 2025 it was $1.23M, up 4.2% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.23M+4.2%
FY2024Dec 31, 2024$1.18M-54.3%
FY2023Dec 31, 2023$2.58M+558.5%
FY2022Dec 31, 2022$391.73K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$600.00K+16.5%
Q1 FY2026Mar 31, 2026$186.00K-4.1%
Q4 FY2025Dec 31, 2025$374.00K+31.2%
Q3 FY2025Sep 30, 2025$145.00K-65.1%
Q2 FY2025Jun 30, 2025$515.00K+3875.3%
Q1 FY2025Mar 31, 2025$194.00K-58.4%
Q4 FY2024Dec 31, 2024$285.00K-87.6%
Q3 FY2024Sep 30, 2024$415.00K+744.7%
Q2 FY2024Jun 30, 2024$12.96K-74.1%
Q1 FY2024Mar 31, 2024$466.61K+150.7%
Q4 FY2023Dec 31, 2023$2.29M–
Q3 FY2023Sep 30, 2023$49.13K–
Q2 FY2023Jun 30, 2023$49.96K–
Q1 FY2023Mar 31, 2023$186.12K–

More Pelthos Therapeutics figures

See a number that looks wrong?